1. Generics Bulletin
  2. >>Legal & IP

New COVID-19 Vaccine Patent Database Launched

Ten Products Listed So Far

 
• By Ian Schofield

As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.

Database on a floating cloud
A new resource for COVID-19 vaccine patents is now available • Source: Alamy

A new database of patents on COVID-19 vaccines has been launched by the Medicines Patent Pool, an organization that arranges voluntary licensing deals to help improve access to effective and affordable medicines for people in low and middle income countries.

The VaxPal database builds on 10 years of experience with the MPP’s MedsPal database, which contains information on the patent status of essential medicines, according to the pool, which last month said it was ready to help with voluntary licensing and technology transfer for COVID-19 vaccines

More from Legal & IP

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Generics Bulletin